Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 5, 2005, Pages 1082-1089

  Kurian, Allison W ^a   Mills, Meredith A ^a   Jaffee, Margo ^b   Sigal, Bronislava M ^a   Chun, Nicolette M ^a   Kingham, Kerry E ^a   Collins, Laura C ^c   Nowels, Kent W ^a   Plevritis, Sylvia K ^a   Garber, Judy E ^b   Ford, James M ^a   Hartman, Anne Renee ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER RISK; CANCER SCREENING; CASE REPORT; FEMALE; GENE MUTATION; HUMAN; LAVAGE; ONCOGENE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; BREAST NEOPLASMS; CATHETERIZATION; CYTODIAGNOSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRRIGATION; MAGNETIC RESONANCE IMAGING; MAMMARY GLANDS, HUMAN; MAMMOGRAPHY; MIDDLE AGED; PILOT PROJECTS; PREMENOPAUSE; RISK ASSESSMENT; RISK FACTORS;

EID: 20844440701     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0776     Document Type: Article

References (54)

1. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681-5.
2. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57:1457-62.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
5. Wagner TM, Moslinger R, Langbauer G, et al. Attitude towards prophylactic surgery and effects of genetic counseling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 2000; 82:1249-53.
6. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003;21:1675-81.
7. Bouchard L, Blancquaert I, Eisinger F, et al. Prevention and genetic testing for breast cancer: variations in medical decisions. Soc Sci Med 2004;58:1085-96.
8. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
9. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-7.
10. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-62.
11. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
12. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
13. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.
14. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81.
15. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-6.
16. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002;102:91-5.
17. Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004;100: 2079-83.
18. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000;63:53-60.
19. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000;215:267-79.
20. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-31.
21. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high risk population. AJR Am J Roentgenol 2003;181:619-26.
22. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
23. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25.
24. Hartman AR, Daniel BL, Kurian AW, et al. Breast MRI screening and ductal lavage in women at high genetic risk for breast cancer. Cancer 2004; 100:479-89.
25. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
26. Page DL, Dupont WD, Rogers LW. Breast cancer risk of lobular-based hyperplasia after biopsy: "ductal" pattern lesions. Cancer Detect Prev 1986; 9:441-8.
27. Stampfer MR, Yaswen P. Culture models of human mammary epithelial cell transformation. J Mammary Gland Biol Neoplasia 2000;5:365-78.
28. Fabian CJ, Kimler BF. Breast cancer chemoprevention: current challenges and a look toward the future. Clin Breast Cancer 2002;3:113-24.
29. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8:3105-17.
30. King BL, Tsai SC, Gryga ME, et al. Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin Cancer Res 2003;9:1509-16.
31. Isaacs C, Cavalli LR, Cohen Y, et al. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from high-risk patients. Breast Cancer Res Treat 2004;84:99-105.
32. Chagpar A, Evelegh M, Pritsche HA, Krishnamurthy S, Hunt KK, Kuerer HM. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer 2004;100:2549-54.
33. Chatterton RJ, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH. Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:928-35.
34. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357: 1335-6.
35. Wrensch MR, Petrakis NL, King EB, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992;135:130-41.
36. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92:1217-27.
37. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001;93:1624-32.
38. Hartman AR, Kurian AW, Mills MA, et al. Results from a pilot breast cancer screening trial using a combination of clinical breast exam, mammography, breast MRI, and ductal lavage in a high-risk population. Proceedings of the San Antonio Breast Cancer Symposium [abstract #114]. Breast Cancer Res Treat 2003;82:S1.
39. Brogi E, Robson M, Panageas KS, Casadio C, Ljung BM, Montgomery L. Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. Cancer 2003;98:2170-6.
40. Khan SA, Wiley EL, Rodriguez N, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 2004; 96:1510-7.
41. Wrensch M, Petrakis NL, King EB, Lee MM, Miike R. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol 1993;137:829-33.
42. Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001;93:1791-8.
43. Claus EB, Risch N, Thompson WB. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28:115-20.
44. Berry DA, Parmigiani G, Sanchez J, Schildkraut G, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
45. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
46. Kurian AW, Mills MA, Nowels KW, et al. Ductal lavage of non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high genetic risk for breast cancer [abstract]. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 145, 2004;9535.
47. Wrensch MR, Petrakis NL, Gruenke LD, et al. Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res Treat 1990;15:39-51.
48. Maddux AJ, Ashfaq R, Naftalis E, Leitch AM, Hoover S, Euhus D. Patient and duct selection for nipple duct lavage. Am J Surg 2004;188:390-4.
49. Sharma P, Klemp JR, Simonsen M, et al. Failure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimens. Breast Cancer Res Treat 2004;87:59-64.
50. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003; 97:1601-8.
51. Pierce L, Levin A, Rebbeck T, et al. Ten-year outcome of breast-conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA1/2 mutations: results from an international collaboration. Proceedings of the San Antonio Breast Cancer Symposium [abstract #5]. Breast Cancer Res Treat 2003;82:S1.
52. Antill Y, Murray W, Lindeman G, House C, Phillips G, Mitchell G. Ductal lavage in BRCA1/2 mutation-carriers: initial experience. Proceedings of the San Antonio Breast Cancer Symposium [abstract #4013]. Breast Cancer Res Treat 2004;88:S1.
53. Raafat AM, Hofseth LJ, Li S, Bennett JM, Haslam SZ. A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: enhanced proliferative response to estrogen in late postmenopausal mice. Endocrinology 1999;140:2570-80.
54. Golewale NH, Bryk M, Nayar R, Didwania A, Hou N, Khan SA. Technical modifications of ductal lavage to improve cell yield. Proceedings of the San Antonio Breast Cancer Symposium [abstract #1024]. Breast Cancer Res Treat 2003;82:S1.